Aerobic Exercise Overcomes the Age-Related Insulin Resistance of Muscle Protein Metabolism by Improving Endothelial Function and Akt/Mammalian Target of Rapamycin Signaling

Abstract

Muscle protein metabolism is resistant to insulin’s anabolic effect in healthy older subjects. This is associated with reduced insulin vasodilation. We hypothesized that aerobic exercise restores muscle protein anabolism in response to insulin by improving vasodilation in older subjects. We measured blood flow, endothelin-1, Akt/mammalian target of rapamycin (mTOR) signaling, and muscle protein kinetics in response to physiological local hyperin-sulinemia in two groups of older subjects following a bout of aerobic exercise (EX group: aged 70 ± 2 years; 45-min treadmill walk, 70% heart rate max) or rest (CTRL group: aged 68 ± 1 years). Baseline endothelin-1 was lower and blood flow tended to be higher in the EX group, but protein kinetics was not different between groups. Insulin decreased endothelin-1 (P < 0.05) in both groups, but endothelin-1 remained higher in the CTRL group (P < 0.05) and blood flow increased only in the EX group (EX group: 3.8 ± 0.7 to 5.3 ± 0.8; CTRL group: 2.5 ± 0.2 to 2.6 ± 0.2 ml · min⁻¹ · 100 ml leg⁻¹). Insulin improved Akt phosphorylation in the EX group and increased mTOR/S6 kinase 1 phosphorylation and muscle protein synthesis (EX group: 49 ± 11 to 89 ± 23; CTRL group: 58 ± 8 to 57 ± 12 nmol · min⁻¹ · 100 ml leg⁻¹) in the EX group only (P < 0.05). Because breakdown did not change, net muscle protein balance became positive only in the EX group (P < 0.05). In conclusion, a bout of aerobic exercise restores the anabolic response of muscle proteins to insulin by improving endothelial function and Akt/mTOR signaling in older subjects.

Sarcopenia is an age-dependent loss of skeletal muscle mass, strength, and quality, which may lead to weakness of the lower extremities, slowing of gait speed, and increased risk of falls (1–3). Sarcopenia is a multifactorial disorder, and evidence is accumulating that a reduced response of skeletal muscle to anabolic stimuli is an important contributing factor. For example, we and others (4,5) have previously shown that healthy aging is associated with a blunted muscle protein anabolic response to hyperaminoacidemia with hyperinsulinemia. Nonetheless, muscle protein synthesis and breakdown in the fasting state may not necessarily change with age (6) and may respond normally to a simple amino acid stimulus (7–10).

Insulin is a potent anabolic stimulus for skeletal muscle. We have recently shown that physiological hyperinsulinemia increases skeletal muscle protein synthesis and anabolism in young healthy subjects, as long as blood flow and amino acid delivery to the muscle are stimulated by insulin (11). Thus, it appears that the insulin-induced modulation of muscle perfusion and nutrient availability is necessary for the anabolic response of muscle protein synthesis to insulin. Furthermore, insulin and amino acids both can stimulate the mammalian target of rapamycin (mTOR) signaling pathway (12). Specifically, insulin promotes the phosphorylation of Akt, an upstream regulator of mTOR, and enhances mTOR signaling to its downstream effectors 4E-binding protein 1 (4EBP1) and ribosomal S6 kinase 1 (S6K1), which are key regulators of translation initiation and protein synthesis (13). On the other hand, amino acids (in particular leucine) can directly activate mTOR kinase activity, resulting in an even more potent stimulation of translation initiation, elongation, and protein synthesis (13).

Healthy aging is also associated with a decreased insulin-induced vasodilation due to dysfunction of the endothelial-dependent vasodilation (14–16), which is normally initiated by insulin via activation of the endothelial NO synthase (17,18). In a recent study of healthy older subjects, we showed that such a vasomotor dysfunction is associated with increased endothelin-1 concentrations and a selective resistance of skeletal muscle protein synthesis to the anabolic action of insulin (16). This novel finding raises the question as to whether interventions that are known to improve endothelial-dependent vasodilation and/or insulin sensitivity may also improve muscle protein synthesis in response to insulin in older subjects.

Aerobic exercise improves endothelial function in older subjects (15) and is also important in the prevention and treatment of type 2 diabetes as it increases insulin sensitivity and glucose tolerance (19–21). These positive effects may be demonstrated in both patients with type 2 diabetes and normal subjects even after a single bout of aerobic exercise and persist for at least 48 h after exercise (21–27). On the other hand, as opposed to progressive resistance exercise, moderate or even strenuous aerobic exercise has only minimal direct effects on muscle protein metabolism, because it stimulates muscle protein synthesis only during the exercise bout, and these effects dissipate in the immediate postexercise period (28).

We hypothesized that a single bout of aerobic exercise performed before an insulin challenge will significantly improve endothelial function and insulin-induced vasodilation and, as a result, will improve the anabolic response of skeletal muscle protein synthesis to insulin in healthy older subjects. To test this hypothesis, we measured leg blood flow, endothelin-1 concentrations, phosphorylation of the Akt/mTOR signaling pathway, and muscle protein kinetics in healthy, nondiabetic, untrained older subjects at baseline and during an insulin challenge that was preceded by either a bout of moderate aerobic exercise (~20 h before the beginning of the measurements) or rest.

RESEARCH DESIGN AND METHODS

We studied 13 older subjects (10 men and 3 women) from the Los Angeles metropolitan area and the greater Houston/Galveston area. All subjects provided informed written consent before participating in the study, which was approved by the institutional review boards of the University of Southern California (Los Angeles, CA) and the University of Texas Medical Branch (Galveston, TX).

All subjects were healthy, nondiabetic, and physically active (no impairments in the activities of daily living or instrumental activities of daily living) but were not engaged in an exercise training program. Screening was performed with clinical history, physical examination, and laboratory tests including blood count, liver and kidney function tests, coagulation profile, fasting blood glucose, oral glucose tolerance tests, hepatitis B/C and HIV screening, thyroid-stimulating hormone, lipid profile, urinalysis, drug screening, and resting electrocardiogram. Subjects with normal results were randomly assigned to either the aerobic exercise group (EX group: 45-min treadmill walk at 70% of maximum heart rate [HR_max] performed the afternoon before the experiment) or a control group (CTRL group) not exercising on the day before the experiment. Subjects randomized to the EX group underwent exercise stress testing at least 1 week before the experiment to exclude individuals with silent cardiac ischemia and measure HR_max and oxygen consumption (V_O2max). Characteristics of subjects meeting eligibility criteria are summarized in Table 1.

TABLE 1.

Characteristics of the study subjects

Subject characteristics	Control	Exercise	P
n	7	6
Sex (men/women)	5/2	5/1	0.61
AGE	70 ± 2	68 ± 1	0.52
Body weight (kg)	80 ± 3	85 ± 3	0.41
Height (cm)	172 ± 5	180 ± 2	0.37
BMI (kg/m2)	27.7 ± 1.5	26.7 ± 1.1	0.73
Leg volume (ml)	9,547 ± 460	9,697 ± 414	0.87

Data are means ± SE.

We measured blood flow, muscle protein, amino acid, and glucose kinetics in the postabsorptive basal state (0–300 min) and during insulin infusion (300–480 min) in the EX and CTRL groups. The afternoon before the study, each subject was admitted to the University of Southern California or the University of Texas Medical Branch General Clinical Research Center. At 1600 h, subjects assigned to the EX group performed a 45-min treadmill walk at 70% HR_max. Briefly, the heart rate was continuously monitored throughout the exercise bout, while treadmill speed and inclination were adjusted to reach and maintain the heart rate at 70% HR_max. At 1830 h, all subjects were fed a standard dinner (one-third of their estimated daily caloric requirements) and given a snack at 2200 h, after which only water ad libitum was allowed until the end of the experiment. The next morning, polyethylene catheters were inserted into a forearm vein for tracer and dextrose infusion, in a contralateral hand or wrist vein for arterialized blood sampling, and in the femoral artery and vein of one leg for blood sampling. The arterial catheter was also used for infusion of insulin (Humulin R; Eli Lilly, Indianapolis, IN) and indocyanine green (ICG) (Akorn, Buffalo Grove, IL).

At 0730 h, after drawing a blood sample to measure background phenylalanine enrichment and ICG concentration, a primed (2 μmol/kg) continuous infusion of L-[ring-¹³C₆]phenylalanine (0.05 μmol · kg⁻¹ · min⁻¹; Cambridge Isotope Laboratories, Andover, MA) was started and maintained at a constant rate until the end of the experiment (Fig. 1). After 2 h, the first muscle biopsy was taken from the lateral portion of the vastus lateralis of the leg with the femoral catheters, using a 5-mm Bergström biopsy needle, aseptic procedure, and local anesthesia with 1% lidocaine injected subcutaneously and on the muscle fascia. The muscle sample (150–400 mg) was quickly rinsed with ice-cold saline, blotted, and immediately frozen in liquid nitrogen and stored at −80°C until analysis. At 230 min, continuous ICG infusion was started in the femoral artery (0.5 mg/min) and maintained until 270 min. During ICG infusion, blood samples were taken four times, at 10-min intervals, from femoral and hand veins to measure ICG concentration. Subsequently, between 270 and 300 min, four blood samples were taken from the femoral artery and vein to measure glucose concentrations and phenylalanine concentrations and enrichments; four other samples were drawn from hand and femoral veins to measure systemic and femoral insulin concentration, respectively. At 300 min, a second muscle biopsy was taken as previously described.

FIG. 1.

Study design. Blood and muscle sampling are indicated by arrows. A detailed description of the study design is provided in the text.

Immediately after the second biopsy, an insulin infusion was initiated directly into the femoral artery (0.15 mU · min⁻¹ · 100 ml leg⁻¹) to expose the leg muscle to postprandial insulin concentrations. This technique allowed us to avoid a major systemic hyperinsulinemia and the consequent dramatic reduction in blood amino acid concentrations (11,29). During insulin infusion, blood samples (0.5 ml) were taken every 5–10 min to monitor plasma glucose concentration, and 20% dextrose was infused at a variable rate as necessary to maintain plasma glucose at the basal value (euglycemic clamp).

Between 410 and 450 min, ICG was again infused to measure leg blood flow, and blood samples were taken between 420 and 450 min and 450 and 480 min to measure ICG concentrations, phenylalanine and glucose enrichments and concentrations, and insulin concentrations, as described for the basal period. At 480 min, before stopping the tracer and insulin infusion, a third muscle biopsy was taken as described above.

Analyses

Plasma insulin and endothelin-1 concentrations were determined by enzyme-linked immunosorbent assay (Linco Research, St. Charles, MO). Plasma glucose concentration was measured using an automated glucose analyzer (YSI, Yellow Springs, OH). Serum ICG concentration was measured spectrophotometrically (Beckman Coulter, Fullerton, CA) at λ = 805 nm (30,31).

Blood phenylalanine concentrations and enrichments were determined by gas chromatography–mass spectrometry (Agilent Technologies, Palo Alto, CA) as previously described (32). We measured only phenylalanine concentration because it is a good predictor of insulin-induced concentration changes in all essential amino acids (33).

Muscle tissue free amino acids and proteins were extracted as previously described (32). Intracellular free phenylalanine concentrations and enrichments of were determined by gas chromatography–mass spectrometry as previously described (32). Mixed muscle protein–bound phenylalanine enrichment was analyzed by gas chromatography–mass spectrometry after protein hydrolysis and amino acid extraction (32) using the external standard curve approach (34).

Total and phosphorylated Akt, mTOR, 4EBP1, and S6K1 in skeletal muscle samples were determined by SDS-PAGE and immunoblotting (BioRad, Hercules, CA) as previously described (35). The phospho and total primary antibodies used are listed in Fig. 3. Total content for each measured protein was detected using an antibody dilution of 1:1,000. Phosphorylation and total protein were normalized to a rodent standard (Precision Plus protein standard; BioRad). Final data were expressed as normalized protein phosphorylation relative to normalized total protein.

FIG. 3.

Phosphorylation of Akt/PKB, mTOR, 4E-BP1, and S6K1 in two groups of older subjects at baseline and during insulin infusion performed ~20 h following rest (Control: n = 5 for Akt/PKB and mTOR; n = 4 for 4E-BP1 and S6K1) or aerobic exercise (Exercise: n = 6). We used the following phospho and total primary antibodies (Cell Signaling, Beverly, MA): phospho-mTOR (Ser²⁴⁴⁸, cat. no. 2971, lot no. 9; 1:1,000), phospho-p70 S6K1 (Thr³⁸⁹, cat. no. 9234, lot no. 2; 1:500), phospho-Akt (Ser⁴⁷³, cat. no. 4058, lot no. 6; 1:500), and phospho-4EBP1 (Thr^37/46, cat. no. 2971; 1:1,000). Anti-rabbit IgG horseradish peroxidase–conjugated secondary antibody was purchased from Amersham Bioscience (1:2,000). Values are means ± SE. *P < 0.05 vs. basal, #P < 0.05 vs. control. □, basal; ■, insulin. Bas, basal; Ins, insulin; MW, molecular weight.

Calculations

Muscle phenylalanine kinetic parameters were calculated using both the two- and the three-pool arteriovenous balance models because each model provides unique information regarding leg plasma (two-pool) and intracellular (three-pool) amino acid kinetics (11). The models’ assumptions and validation are extensively reviewed (36). The two- and three-pool model parameters were calculated as follows.

$$\text{Phenylalanine}\text{delivery}\text{to}\text{the}\text{leg}=F_{\text{in}}=\text{BF}\times C_{\text{A}}$$ (1)

$$\text{Phenylalanine}\text{output}\text{from}\text{the}\text{leg}=F_{\text{out}}=\text{BF}\times C_{\text{V}}$$ (2)

$$\text{Net}\text{balance}=\text{NB}=\text{BF}\times (C_{\text{A}}-C_{\text{V}})$$ (3)

$$\text{Total}\text{leg}\text{rate}\text{of}\text{appearance}=\text{total}{R}_{\text{a}}=\text{BF}\times C_{\text{A}}\times E_{\text{A}}/E_{\text{V}}$$ (4)

$$\begin{array}{l}\text{Release}\text{in}\text{blood}\text{from}\text{proteolysis}=\text{leg}{R}_{\text{a}}=\text{total}{R}_{\text{a}}-F_{\text{in}}=\text{BF}\times C_{\text{A}}\\ \times ([E_{\text{A}}/E_{\text{V}}]-1)\end{array}$$ (5)

$$\begin{array}{l}\text{Rate}\text{of}\text{disappearance}\text{from}\text{blood}=\text{leg}{R}_{\text{d}}=\text{leg}{R}_{\text{a}}+\text{NB}=\text{BF}\times ([C_{\text{A}}\\ \times E_{\text{A}}/E_{\text{V}}]-C_{\text{V}})\end{array}$$ (6)

$$\text{Muscle}\text{inward}\text{transport}=F_{\text{M},\text{A}}=([C_{\text{V}}\times \{E_{\text{M}}-E_{\text{V}}\}/\{E_{\text{A}}-E_{\text{M}}\}]+C_{\text{V}})\times \text{BF}$$ (7)

$$\text{Muscle}\text{outward}\text{transport}=F_{\text{V},\text{M}}=([C_{\text{V}}\times \{E_{\text{M}}-E_{\text{V}}\}/\{E_{\text{A}}-E_{\text{M}}\}]+C_{\text{A}})\times \text{BF}$$ (8)

$$\text{Arteriovenous}\text{shunting}=F_{\text{V},\text{A}}=F_{\text{in}}-F_{\text{M},\text{A}}$$ (9)

$$\text{Release}\text{from}\text{muscle}\text{protein}\text{breakdown}=F_{\text{M},0}=F_{\text{M},\text{A}}\times ([E_{\text{A}}/E_{\text{M}}]-1)$$ (10)

$$\text{Utilization}\text{for}\text{muscle}\text{protein}\text{synthesis}=F_{0,\text{M}}=F_{\text{M},0}+\text{NB}$$ (11)

$$\text{Intracellular}\text{amino}\text{acid}\text{availability}=F_{\text{M},\text{A}}+F_{\text{M},0}$$ (12)

where C_A, C_V is plasma phenylalanine concentrations in the femoral artery and vein, respectively. E_A, E_V, and E_M are free phenylalanine enrichments (tracer-to-tracee ratio) in femoral artery and vein and in muscle, respectively. BF is leg blood flow calculated from steady-state ICG concentrations (30,31). Data were expressed per 100 ml of leg volume.

We also measured the fractional synthetic rate (FSR) of mixed muscle proteins by measuring the incorporation rate of the phenylalanine tracer into the proteins (ΔEp/t) and using the precursor-product model to calculate the synthesis rate as follows (37): FSR = (ΔEp/t)/([E_M{1} + E_M{2}]/2) × 60 × 100. ΔEp is the increment in protein-bound phenylalanine enrichment between two sequential biopsies, t is the time between the two sequential biopsies, E_M{1} and E_M{2} are the phenylalanine enrichments in the free intracellular pool in the two sequential biopsies. Data are expressed in the percentage per hour.

Leg glucose utilization was calculated as net glucose uptake across the leg: leg glucose uptake = BF × (C_A − C_V).

To determine the degree of muscle tissue exposure to insulin, we calculated the insulin delivery rate to the leg to account for recycling from the systemic circulation (16). Further, changes in blood flow can affect insulin concentration during constant infusion. Because insulin was infused in the artery, arterial insulin concentration was not measurable, and insulin delivery was estimated using the femoral insulin concentration (Ins_FV) as follows: insulin delivery = Ins_FV × BF.

Since some insulin is taken up by the muscle cells after binding to the insulin receptor, this method may slightly underestimate the total insulin delivery rate, but for the above reasons we found it preferable to simply relying on the calculated dose.

Statistical analysis

Sex differences between groups were analyzed using the χ² test. Subjects’ characteristics and baseline values for all measured variables were analyzed using one-way ANOVA. The effects of the prior bout of exercise on the response variables of the basal period and during insulin infusion were compared using ANOVA for repeated measures, the main effects being group (the EX and CTRL groups) and time (basal and insulin infusion). Post hoc testing was performed using the Tukey-Kramer test. If baseline values were significantly different or tended to be different (P < 0.10), we also performed an ANCOVA using baseline values as covariates. Differences were considered significant at P < 0.05. P for trend was set at P < 0.10. Data are the means ± SE.

RESULTS

Insulin and glucose

Blood glucose and insulin concentrations and kinetics across the leg are shown in Table 2. Systemic and femoral vein insulin concentrations were not different at baseline and significantly increased in both groups during insulin infusion, but the change was larger in the CTRL group (P < 0.05). However, because of the differences in leg blood flow (see below), insulin delivery to the leg was not different between groups at baseline and significantly increased during insulin infusion in both groups, with no differences between groups. Plasma arterial glucose concentrations were not different between groups at baseline and did not change during insulin infusion with euglycemic clamp. However, the exogenous glucose infusion rate and leg glucose uptake during insulin infusion were significantly higher in the EX group (P < 0.05).

TABLE 2.

Endothelial function parameters, insulin and glucose concentrations, and kinetics at baseline and during insulin infusion

	CTRL group		EX group		P
	Basal	Insulin	Basal	Insulin	Group	Time	Interaction
Endothelial function
Endothelin-1 (pg/ml)	3.53 ± 0.72	2.46 ± 0.39	1.85 ± 0.08	1.60 ± 0.10	<0.01	0.02	0.14
Blood flow (ml · min−1 · 100 ml leg−1)	2.6 ± 0.2	2.7 ± 0.2	3.8 ± 0.7	5.3 ± 0.8	0.02	<0.01	<0.01
Insulin
Systemic concentration (μU/ml)	8.5 ± 1.0	24.0 ± 2.4	6.3 ± 0.8	15.0 ± 1.2	<0.01	<0.0001	0.06
Femoral vein concentration (μU/ml)	8.5 ± 1.0	83.4 ± 5.2	6.3 ± 0.8	46.7 ± 5.1	<0.001	<0.0001	0.001
Delivery to the leg (μU · min−1 · 100 ml leg−1)	22 ± 3	218 ± 11	23 ± 4	255 ± 57	0.48	<0.0001	0.45
Glucose
Femoral artery concentration (mmol/l)	4.7 ± 0.2	4.5 ± 0.2	4.9 ± 0.1	5.0 ± 0.2	0.19	0.44	0.36
Infusion rate (μmol · kg−1 · min−1)*	—	10.4 ± 0.8	—	13.6 ± 0.9	0.02	—	—
Leg uptake (μmol · min−1 · 100 ml leg−1)*	—	1.8 ± 0.4	—	3.6 ± 0.6	0.03	—	—

Data are means ± SE. Statistical analysis performed using ANOVA with repeated measures for all parameters except those marked with *, which were analyzed using one-way ANOVA. Boldface data indicate statistical significance.

Endothelin-1 concentrations and leg blood flow

Plasma endothelin-1 concentrations in the femoral vein and leg blood flow are shown in Table 2 and Fig. 2. Endothelin-1 concentrations were significantly lower (P < 0.05) in the EX group at baseline and significantly decreased during insulin infusion in both groups (P = 0.02) with no time-by-group interaction. Leg blood flow at baseline tended to be higher in the EX than CTRL group (P = 0.08). In response to insulin, leg blood flow significantly increased only in the EX group (P < 0.05), while no change was observed in the CTRL group. ANCOVA using baseline values as covariates confirmed the results for both blood flow and endothelin-1.

FIG. 2.

Plasma endothelin-1 concentrations, blood flow, and muscle protein FSR in two groups of older subjects at baseline and during insulin infusion performed ~20 h following rest (Control: n = 7) or aerobic exercise (Exercise: n = 6). Values are means ± SE. *P < 0.05 vs. basal, #P < 0.05 vs. control. □, basal; ■, insulin.

Phenylalanine concentrations and enrichments

Average phenylalanine concentrations in the femoral artery and vein and in the muscle are reported in Table 3. Phenylalanine concentrations in the artery and in the vein were not different at baseline and slightly, but significantly, decreased in both groups with no differences between groups. Phenylalanine concentrations in muscle were significantly lower in the EX group at baseline (P < 0.01) and decreased during insulin infusion in both groups with no time-by-group interaction. ANCOVA using the baseline values as covariates confirmed these results. Phenylalanine enrichments in the femoral artery and vein and in the muscle tissue were not different between groups in the basal period and were at steady state during both sampling periods (data not shown). Phenylalanine enrichment in the femoral artery and vein increased slightly but significantly (P < 0.01) during insulin infusion in both groups, with no group differences. Phenylalanine enrichment in the muscle tissue tended to increase in both groups (P < 0.06) with no significant group differences either at baseline or during insulin infusion.

TABLE 3.

Phenylalanine concentrations at baseline and during insulin infusion

	CTRL group		EX group		P
	Basal	Insulin	Basal	Insulin	Group	Time	Interaction
Femoral artery (μmol/l)	61 ± 2	56 ± 2	62 ± 2	59 ± 2	0.31	<0.001	0.11
Femoral vein (μmol/l)	67 ± 2	56 ± 1	68 ± 1	58 ± 2	0.59	<0.0001	0.65
Muscle tissue (μmol/l)	127 ± 11	95 ± 11	85 ± 5	81 ± 8	0.02	0.05	0.12

Data are means ± SE. Boldface data indicate statistical significance.

Amino acid kinetics

Leg and muscle phenylalanine kinetics are shown in Table 4. All kinetic parameters were not significantly different between groups in the basal period. With insulin infusion, phenylalanine delivery to the leg increased in the EX group only (P < 0.01). Phenylalanine output from the leg increased in the EX group and decreased in the CTRL group, resulting in a significant treatment-by-group interaction (P < 0.01). Because of a trend for basal phenylalanine delivery and output to be higher in the EX group (P = 0.07), an ANCOVA was carried out for both parameters using the basal values as covariates and confirmed the ANOVA results. Phenylalanine leg R_a significantly decreased in the CTRL group (P = 0.04), whereas no change was observed in the EX group. In contrast, phenylalanine leg R_d increased only in the EX group during insulin infusion (P < 0.01), whereas it did not change in the CTRL group.

TABLE 4.

Phenylalanine kinetics at baseline and during insulin infusion

	CTRL group		EX group		P
	Basal	Insulin (nmol · min−1 · 100 ml leg−1)	Basal	Insulin (nmol · min−1 · 100 ml leg−1)	Group	Time	Interaction
Delivery to the leg	156 ± 12	145 ± 8	234 ± 43	309 ± 47	0.01	<0.01	<0.01
Output from the leg	171 ± 13	149 ± 10	255 ± 46	300 ± 45	0.02	0.23	<0.01
Release in the blood from proteolysis (Ra)	63 ± 10	44 ± 9	66 ± 14	70 ± 19	0.32	0.21	0.04
Disappearance from the blood (Rd)	48 ± 9	40 ± 7	45 ± 11	79 ± 19	0.22	0.02	<0.01
Muscle inward transport	113 ± 20	75 ± 11	193 ± 46	250 ± 47	0.01	0.47	0.02
Muscle outward transport	128 ± 21	79 ± 11	214 ± 48	241 ± 45	0.01	0.62	0.05
Arteriovenous shunting	43 ± 11	70 ± 12	41 ± 13	59 ± 28	0.76	0.06	0.77
Intracellular availability	186 ± 27	136 ± 21	263 ± 58	330 ± 60	0.03	0.49	<0.01
Release from muscle protein breakdown	73 ± 9	61 ± 14	70 ± 14	80 ± 23	0.55	0.95	0.18
Utilization for muscle protein synthesis	58 ± 8	57 ± 12	49 ± 11	89 ± 23	0.44	0.02	0.03
Net balance	−15 ± 2	−2 ± 2	−21 ± 4	9 ± 4	0.43	<0.0001	<0.01

Data are means ± SE. Boldface data indicate statistical significance.

Muscle phenylalanine inward and outward transport decreased in the CTRL group and increased in the EX group, resulting in significant treatment-by-group interactions (P < 0.05). ANCOVA performed on these two parameters, because of a trend for the baseline values to be higher in the EX group (P = 0.07), confirmed the ANOVA results. Phenylalanine intracellular availability increased with insulin in the EX group, whereas it decreased in the CTRL group, resulting in a significant time-by-group interaction (P < 0.01). Phenylalanine arteriovenous shunting increased significantly in both groups with no group differences. Phenylalanine release from proteolysis did not change significantly with insulin infusion in either group. Phenylalanine utilization for muscle protein synthesis increased significantly during insulin infusion in the EX group (P = 0.03), but it did not change in the CTRL group. As a result, phenylalanine net balance across the leg improved significantly in both groups in response to insulin (P < 0.0001), but the increase was significantly larger in the EX group such that net balance became positive only in the EX group (P < 0.01), indicating net muscle protein anabolism.

Mixed muscle FSR

The mixed muscle protein FSR (%/h) (Fig. 2) was not different between groups in the basal state (CTRL group: 0.063 ± 0.007; EX group: 0.062 ± 0.005). Insulin infusion significantly increased FSR in the EX group (P < 0.05) but not in the CTRL group (CTRL group: 0.062 ± 0.005; EX group: 0.099 ± 0.005).

Insulin and mTOR signaling proteins

Insulin and mTOR signaling is reported in Fig. 3. Akt/PKB^Ser473 phosphorylation increased significantly with insulin (time effect P < 0.05), but the response was significantly greater in the EX group (P < 0.05). Insulin infusion significantly increased mTOR^Ser2448 phosphorylation only in the EX group (P < 0.05). 4EBP1^Thr37/46 phosphorylation increased in both groups during insulin infusion (time effect P < 0.05), with no difference between groups. S6K1^Thr389 phosphorylation increased significantly with insulin (time effect P < 0.05), but the increase was larger in the EX group (P < 0.05).

DISCUSSION

Our study indicates for the first time that a single bout of moderate aerobic exercise overcomes the muscle protein insulin resistance and restores the physiological anabolic response of muscle protein synthesis to insulin in older individuals. These exciting results indicate that a moderate-intensity aerobic exercise that can be performed by most ambulatory older individuals may be an important tool to combat sarcopenia and frailty of aging. The effect of aerobic exercise on muscle protein anabolism in these older individuals appears to be due, at least in part, to improvements in endothelial function, insulin-induced vasodilation, and nutrient delivery. Specifically, we found that muscle protein synthesis and net balance significantly increased during insulin infusion only if the infusion was preceded by a bout of aerobic exercise. Such an effect was directly associated with an increase in blood flow, which, in turn, was accompanied by a significant increase in amino acid delivery and transport into the muscle tissue, and by enhanced mTOR signaling. In contrast, insulin did not exert any effect on either blood flow or muscle amino acid and protein turnover in the subjects resting before the insulin challenge.

These novel data also indicate for the first time that insulin-induced vasodilation is an important contributor to muscle protein anabolism in older subjects. If we interpret these results in light of our recently published study (11) in young adults demonstrating that physiological hyperinsulinemia stimulates muscle protein synthesis as long as it increases blood flow and amino acid delivery to the muscle tissue, we conclude that vasodilation is a major mechanism by which insulin stimulates muscle protein synthesis throughout the adult life. Insulin-induced vasodilation appears to be more rate limiting for muscle protein anabolism than for glucose uptake. Studies on the regulation of vascular tone and glucose metabolism by insulin have uncovered a fascinating picture whereby insulin appears to rapidly recruit nutritive capillaries, which precedes the insulin’s effects on intracellular signaling and glucose uptake in muscle (38). However, the overall effect of insulin-induced vasodilation on muscle glucose metabolism is more evident when glucose uptake is high (i.e., when the artery-to-vein glucose concentration gradient is high) (39,40). This occurs because an increased blood flow reduces the arteriovenous glucose gradient and allows for a more uniform exposure of all muscle tissue to adequate blood glucose concentrations necessary to sustain the higher rate of uptake (41). The metabolic effects of insulin-induced vasodilation appear magnified when examining muscle amino acid uptake and utilization and appear to drive the overall muscle protein anabolic response (present study and 11,16,29).

The vascular tone is determined by the fine balance of a complex network of vasodilators and vasoconstrictors, many of which are directly produced by the endothelium (42). Insulin increases muscle perfusion and capillary recruitment by stimulating NO production via activation of endothelial NO synthase (17,18), and it is also well recognized that aging reduces endothelial-derived vasodilation (14–16). The negative effect of aging appears to be also associated with an increased plasma endothelin-1 concentration (16), which is another likely cause of the age-related endothelial dysfunction. Endothelin-1 is produced by vascular endothelial cells (43) and is one of the most powerful endothelial-derived vasoconstrictors (42). Interestingly, recent studies have shown that endothelin-1 receptor blockade enhances the vasodilatory action of insulin in humans (44), and aerobic exercise training for 3 months significantly reduces plasma endothelin-1 concentration in both younger and older subjects (45). Our current study is the first to report that a single bout of aerobic exercise reduces plasma endothelin-1 concentration to youthful levels and normalizes the vasodilatory and muscle protein anabolic response to insulin in older individuals. Considering all these data, it appears that endothelin-1 is potentially a suitable marker of age-related endothelial dysfunction and muscle protein insulin resistance. Further studies are needed to determine the sensitivity and specificity of endothelin-1 as a marker of muscle protein catabolism in older individuals.

Although our data strongly suggest that aerobic exercise normalized the anabolic response of muscle to insulin by improving endothelium-dependent vasodilation, we also found an improvement in insulin signaling. This was associated with a higher regional and whole-body insulin-stimulated glucose uptake in the exercise group, which is consistent with previous reports indicating that a single bout of aerobic exercise enhances insulin sensitivity for up to 48 h in both healthy subjects and in patients with type 2 diabetes (21–27). However, if we analyze the Akt/mTOR signaling results in light of the amino acid and protein kinetics data, interpretation becomes more complicated. In the control subjects, local hyperinsulinemia stimulated muscle Akt^Ser473, 4EBP1^Thr37/46, and S6K1^Thr389 phosphorylation but had no effect on amino acid availability, mTOR^Ser2448 phosphorylation, or muscle protein synthesis. This is consistent with previously published data (5,16) and suggests that increases in insulin signaling in the absence of increased amino acid availability may be insufficient to fully stimulate the mTOR signaling pathway (13). Aerobic exercise enhanced Akt^Ser473 and S6K1^Thr389 phosphorylation, amino acid availability (consequent to improved vasodilation), and mTOR^Ser2448 phosphorylation in response to insulin, resulting in the stimulation of muscle protein synthesis. Thus, by merely considering the present data one can definitely conclude that aerobic exercise restores the normal muscle protein anabolic response to hyperinsulinemia. However, the question remains as to whether this effect of exercise on mTOR signaling and protein synthesis is due to its effect on vasodilation (and amino acid availability), insulin signaling, or both.

Some indirect answers can be derived from the analysis of recent data published by our group, which allow a better understanding of the complex mechanisms underlying the anabolic effect of insulin on muscle proteins. Insulin sensitivity of glucose metabolism is not correlated with the insulin sensitivity of protein metabolism, as the insulin-induced protein anabolic response in muscle is preserved in uncontrolled type 2 diabetes (46). Additionally, we have shown in healthy, insulin-sensitive, younger subjects that increasing insulin doses, which increase glucose uptake in a dose-dependent manner, are unable to stimulate muscle protein anabolism if muscle perfusion and amino acid availability are not simultaneously enhanced (11). Thus, improved insulin signaling following exercise is unlikely the only major mechanism allowing for the restoration of the physiological muscle protein anabolic response to insulin, since improvements in vasodilation and the consequent increases in amino acid availability appear to play an essential role as well.

However, it is also important to underscore how the current data make it apparent that increases in tissue perfusion and amino acid availability are necessary, but not sufficient, to induce an anabolic response of muscle proteins. Indeed, the EX group tended to have a higher baseline blood flow and amino acid delivery, but this did not result in a higher baseline mTOR signaling or muscle protein synthesis. Therefore, it is likely that for insulin to acutely increase human skeletal muscle protein synthesis and anabolism it has to increase not only muscle perfusion and amino acid delivery but also provide adequate signals for an increase in muscle protein translation. Additionally, the higher baseline blood flow with no differences in muscle protein turnover or signaling also indicates that the effect of exercise on the vascular tone is direct and not mediated by increases in insulin sensitivity or muscle metabolism.

Finally, our finding of enhanced Akt signaling following exercise is consistent with some (47,48), but not all (49,50), previous reports. However, in the negative studies (49,50) insulin signaling had been measured immediately after exercise (<6 h), while we measured it 20 h postexercise (48). These data suggest that insulin signaling may be enhanced by aerobic exercise in a time-dependent manner. Future studies on the time course of exercise-induced enhancement of insulin signaling are warranted.

In summary, a single bout of aerobic exercise overcomes the age-related insulin resistance of muscle protein synthesis by reducing endothelial dysfunction, improving muscle perfusion and amino acid availability for the muscle tissue, and enhancing activation of the Akt/mTOR signaling pathway and muscle protein synthesis. Clinical studies are needed to investigate whether aerobic exercise may prevent the loss of muscle mass with aging by improving the muscle anabolic response during feeding.

4EBP1

4E-binding protein 1

FSR

fractional synthetic rate

ICG

indocyanine green

mTOR

mammalian target of rapamycin

S6K1

S6 kinase 1